JP2007515432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515432A5 JP2007515432A5 JP2006545810A JP2006545810A JP2007515432A5 JP 2007515432 A5 JP2007515432 A5 JP 2007515432A5 JP 2006545810 A JP2006545810 A JP 2006545810A JP 2006545810 A JP2006545810 A JP 2006545810A JP 2007515432 A5 JP2007515432 A5 JP 2007515432A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkoxy
- independently
- alkyl
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003545 alkoxy group Chemical group 0.000 claims 65
- 125000000217 alkyl group Chemical group 0.000 claims 53
- 125000004429 atom Chemical group 0.000 claims 37
- 125000001424 substituent group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000004423 acyloxy group Chemical group 0.000 claims 14
- 125000004414 alkyl thio group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000002950 monocyclic group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 8
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 230000008938 immune dysregulation Effects 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 206010019663 Hepatic failure Diseases 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 231100000835 liver failure Toxicity 0.000 claims 4
- 208000007903 liver failure Diseases 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 206010048962 Brain oedema Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 208000006752 brain edema Diseases 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 208000023589 ischemic disease Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 2
- 241000976983 Anoxia Species 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007953 anoxia Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 230000010437 erythropoiesis Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 208000023569 ischemic bowel disease Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 208000019629 polyneuritis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000004354 sulfur functional group Chemical group 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000002287 Keratoconus Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010027910 Mononeuritis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000012896 Peritoneal disease Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 210000003123 bronchiole Anatomy 0.000 claims 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 210000001750 dental cementum Anatomy 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 238000003912 environmental pollution Methods 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 210000004195 gingiva Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 206010019692 hepatic necrosis Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000003903 intestinal lesions Effects 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 231100000149 liver necrosis Toxicity 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013734 mononeuritis simplex Diseases 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 238000012753 partial hepatectomy Methods 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 201000004338 pollen allergy Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000003966 vascular damage Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53018603P | 2003-12-17 | 2003-12-17 | |
| US60/530,186 | 2003-12-17 | ||
| PCT/US2004/041887 WO2005058848A1 (en) | 2003-12-17 | 2004-12-13 | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007515432A JP2007515432A (ja) | 2007-06-14 |
| JP2007515432A5 true JP2007515432A5 (https=) | 2008-02-07 |
| JP4773972B2 JP4773972B2 (ja) | 2011-09-14 |
Family
ID=34700108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545810A Expired - Fee Related JP4773972B2 (ja) | 2003-12-17 | 2004-12-13 | Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7605171B2 (https=) |
| EP (1) | EP1697333A4 (https=) |
| JP (1) | JP4773972B2 (https=) |
| CN (1) | CN1894225A (https=) |
| AU (1) | AU2004299456B2 (https=) |
| CA (1) | CA2547198A1 (https=) |
| WO (1) | WO2005058848A1 (https=) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US7781617B2 (en) | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| EP1806338B1 (en) | 2004-10-12 | 2016-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof |
| KR20080002850A (ko) | 2005-03-23 | 2008-01-04 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
| CA2602474C (en) | 2005-03-23 | 2014-06-10 | Actelion Pharmaceuticals Ltd | Hydrogenated benzo (c) thiophene derivatives as immunomodulators |
| US8017631B2 (en) | 2005-04-26 | 2011-09-13 | Neurosearch A/S | Oxadiazole derivatives and their medical use |
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2006131336A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| BRPI0615133A2 (pt) * | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| PL1932522T3 (pl) * | 2005-10-07 | 2012-09-28 | Kyorin Seiyaku Kk | Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| AU2007209051A1 (en) | 2006-01-24 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Novel pyridine derivatives |
| GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| EP2258700A1 (en) | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| CA2659598A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Amino phosphate derivative and s1p receptor modulator having same as an active ingredient |
| JP5140593B2 (ja) | 2006-08-08 | 2013-02-06 | 杏林製薬株式会社 | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 |
| AR061841A1 (es) * | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
| AU2007292436A1 (en) * | 2006-09-07 | 2008-03-13 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity |
| CA2662852A1 (en) * | 2006-09-07 | 2008-03-13 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| PT2069336E (pt) * | 2006-09-07 | 2013-03-07 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-ilo como agentes imunomoduladores |
| EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
| CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| US7728014B2 (en) | 2006-09-07 | 2010-06-01 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity |
| PL2069335T3 (pl) * | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| ES2393412T3 (es) | 2006-09-21 | 2012-12-21 | Actelion Pharmaceuticals Ltd. | Derivados de fenilo y su uso como inmunomoduladores |
| WO2008039023A1 (en) | 2006-09-29 | 2008-04-03 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists |
| CA2666310C (en) | 2006-10-20 | 2012-07-31 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| US8106070B2 (en) | 2006-10-20 | 2012-01-31 | Merck Sharp & Dohme Corp. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| CA2667003A1 (en) | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| BRPI0808789A2 (pt) * | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
| AU2008241490B2 (en) | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| AU2008240773B2 (en) * | 2007-04-19 | 2013-10-03 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| US8048898B2 (en) | 2007-08-01 | 2011-11-01 | Taisho Pharmaceutical Co., Ltd | Inhibitor of binding of S1P1 |
| PT2195311E (pt) | 2007-08-17 | 2011-05-25 | Actelion Pharmaceuticals Ltd | Derivados de piridina como moduladores do receptor s1p1/edg1 |
| CN104478821B (zh) * | 2007-10-04 | 2016-09-28 | 默克雪兰诺有限公司 | 噁二唑二芳基化合物 |
| MX2010003612A (es) | 2007-10-04 | 2010-04-30 | Merck Serono Sa | Derivados de oxadiazol. |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| CA2707095A1 (en) * | 2007-11-30 | 2009-06-04 | Novartis Ag | Phenyl-oxetanyl-derivatives |
| MX2010005889A (es) | 2007-12-10 | 2010-06-22 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno como agonistas de s1p1/edg1. |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| AU2008340113B2 (en) * | 2007-12-21 | 2014-01-09 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009085847A1 (en) | 2008-01-03 | 2009-07-09 | Allergan, Inc. | Tetrahydroindoles having sphingosine-1-phosphate receptor activity |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| EP2262799B1 (en) * | 2008-03-06 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
| WO2009109907A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
| WO2009109872A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| CA2715317A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| EP3782991A1 (en) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151626A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| UY31922A (es) * | 2008-06-20 | 2010-01-05 | Glaxo Group Ltd | Compuestos |
| MX2011000211A (es) | 2008-07-15 | 2011-03-03 | Sanofi Aventis | Oxazolopirimidinas como agonistas del receptor edg-1. |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| HRP20160890T1 (hr) | 2008-08-27 | 2016-09-23 | Arena Pharmaceuticals, Inc. | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| EP2210890A1 (en) * | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| ES2517265T3 (es) | 2009-03-03 | 2014-11-03 | Merck Serono S.A. | Derivados de oxadiazol piridina |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910688D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2445891A4 (en) * | 2009-06-26 | 2012-11-14 | Glaxo Group Ltd | 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS |
| CA2767585C (en) | 2009-07-16 | 2017-09-26 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| ES2665461T3 (es) * | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| PH12012500940B1 (en) * | 2009-11-13 | 2018-09-26 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| MX2012005560A (es) * | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| CA2784647A1 (en) * | 2009-12-17 | 2011-07-14 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| ES2548683T3 (es) | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| TW201206429A (en) * | 2010-07-08 | 2012-02-16 | Merck Serono Sa | Substituted oxadiazole derivatives |
| US8822510B2 (en) | 2010-07-20 | 2014-09-02 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-Oxadiazole compounds |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| EP2635573B1 (en) | 2010-11-03 | 2014-10-01 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| WO2012074980A2 (en) * | 2010-12-01 | 2012-06-07 | Dara Biosciences, Inc. | Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives |
| AU2011337084A1 (en) * | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Novel pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| MA34910B1 (fr) | 2011-01-19 | 2014-02-01 | Actelion Pharmaceuticals Ltd | Dérivés de 2-methoxy-pyridin-4-yl |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| PH12017502097B1 (en) | 2015-05-20 | 2023-05-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| WO2017004608A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
| WO2017004609A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| KR102482825B1 (ko) | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
| CN106674011B (zh) * | 2016-12-09 | 2019-05-07 | 南京理工大学 | 一种由二甲基亚砜合成茚酮衍生物的方法 |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| CN108939074B (zh) * | 2017-05-22 | 2022-06-10 | 北京蔚蓝之源医药科技有限公司 | 治疗再生障碍性贫血的方法和药物组合物 |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| WO2021175225A1 (zh) * | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 三环类化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH433348A (de) * | 1963-03-04 | 1967-04-15 | Hoffmann La Roche | Verfahren zur Herstellung von substituierten Hydrazinverbindungen |
| DE4124942A1 (de) * | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4427838A1 (de) * | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US6699853B2 (en) * | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
| EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
| ES2251976T3 (es) | 1999-02-11 | 2006-05-16 | Emisphere Technologies, Inc. | Compuestos y composiciones de oxadiazol para aportar agentes activos. |
| ES2316613T3 (es) * | 2001-05-10 | 2009-04-16 | Ono Pharmaceutical Co., Ltd. | Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo. |
| ATE448193T1 (de) * | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| DE60335827D1 (de) * | 2002-12-20 | 2011-03-03 | Merck Sharp & Dohme | 1-(amino)indane als edg-rezeptoragonisten |
| AU2004240586A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
-
2004
- 2004-12-13 EP EP04814111A patent/EP1697333A4/en not_active Withdrawn
- 2004-12-13 US US10/575,790 patent/US7605171B2/en not_active Expired - Fee Related
- 2004-12-13 CA CA002547198A patent/CA2547198A1/en not_active Abandoned
- 2004-12-13 WO PCT/US2004/041887 patent/WO2005058848A1/en not_active Ceased
- 2004-12-13 JP JP2006545810A patent/JP4773972B2/ja not_active Expired - Fee Related
- 2004-12-13 AU AU2004299456A patent/AU2004299456B2/en not_active Ceased
- 2004-12-13 CN CNA2004800372085A patent/CN1894225A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007515432A5 (https=) | ||
| JP2008517915A5 (https=) | ||
| JP2006528980A5 (https=) | ||
| JP2010540593A5 (https=) | ||
| JP2006511579A5 (https=) | ||
| JP2002528493A5 (https=) | ||
| JP2008510762A5 (https=) | ||
| CA2472713A1 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
| JP2002528490A5 (https=) | ||
| JP2020521741A5 (https=) | ||
| EP4001276A1 (en) | Aurora kinase inhibitor and use thereof | |
| JP2020537657A5 (https=) | ||
| JP2009532417A5 (https=) | ||
| JP2020528889A5 (https=) | ||
| CA2513081A1 (en) | Pyrrolopyridazine derivatives | |
| JP2008512380A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2004507552A (ja) | 免疫調節剤としてのリン酸誘導体 | |
| CA2952541A1 (en) | Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
| JP2003531103A5 (https=) | ||
| JP2018528181A5 (https=) | ||
| JP2003525295A5 (https=) | ||
| JP2003507456A5 (https=) | ||
| JP2013523802A5 (https=) | ||
| CA2565852C (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |